Literature DB >> 3935464

Isolation of human hepatic microsomes and their inhibition by cimetidine and ranitidine.

H P Hoensch, H Hutzel, W Kirch, E E Ohnhaus.   

Abstract

Human hepatic microsomes were isolated from wedge biopsies of the liver from 13 patients undergoing abdominal surgery. Ultrasonic homogenisation was used to increase the yield of microsomal monooxygenase activity (7-ethoxycoumarin O-deethylase, NADPH-cytochrome c reductase), resulting in a 30% higher total enzyme activity per g liver than preparation by other techniques. In 4 individual microsomal preparations the influence of cimetidine and ranitidine on Michaelis-Menten kinetics of O-deethylation and of reductase activity were studied. Without the H2-receptor blocking drugs, enzyme kinetics of O-deethylation with a Km of 51.0 +/- 16.4 microM (n = 3) were obtained using Lineweaver-Burke plots. Both, cimetidine and ranitidine inhibited the O-deethylation; cimetidine had a five-fold higher inhibitory affinity (Ki 1.01 and 3.94 mM) to the monooxygenase than ranitidine (Ki 4.96 and 17.70 mM) in the uninduced liver. However, in liver from a patient with induced enzyme activity (Km = 478.0 microM), the Ki of ranitidine was similar to that of cimetidine (Ki ran 3.57 versus Ki cim 2.49 mM). The reductase activity was not inhibited by ranitidine and only marginally so by cimetidine. The results suggest that in human hepatic microsomes oxidative drug metabolism is inhibited by both H2-receptor antagonists. However, the inhibitory potency of the compounds seems to depend on the individual isozyme pattern of the hepatic microsomes. Thus, while cimetidine is an relatively nonspecific enzyme inhibitor, ranitidine might more selectively inhibit induced drug metabolizing enzymes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3935464     DOI: 10.1007/bf00547422

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  37 in total

1.  AN ADAPTIVELY STIMULATED O-DEMETHYLATING SYSTEM IN RAT LIVER MICROSOMES AND ITS KINETIC PROPERTIES.

Authors:  K J NETTER; G SEIDEL
Journal:  J Pharmacol Exp Ther       Date:  1964-10       Impact factor: 4.030

2.  Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver.

Authors:  C H WILLIAMS; H KAMIN
Journal:  J Biol Chem       Date:  1962-02       Impact factor: 5.157

3.  Failure of ranitidine to interact with propranolol.

Authors:  A M Heagerty; C M Castleden; L Patel
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-01

4.  Interaction of H2-receptor antagonists with drug-metabolizing enzymes.

Authors:  J A Bell; A J Gower; L E Martin; E N Mills; W P Smith
Journal:  Biochem Soc Trans       Date:  1981-02       Impact factor: 5.407

Review 5.  Ranitidine: a new H2-receptor antagonist.

Authors:  J B Zeldis; L S Friedman; K J Isselbacher
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

Review 6.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

7.  The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat.

Authors:  O Pelkonen; J Puurunen
Journal:  Biochem Pharmacol       Date:  1980-11-15       Impact factor: 5.858

8.  Monooxygenase enzyme activity in alcoholics with varying degrees of liver damage.

Authors:  H Hoensch; F Hartmann; H Schomerus; P Bieck; W Dölle
Journal:  Gut       Date:  1979-08       Impact factor: 23.059

9.  Comparative metabolism of benzo[a]pyrene and drugs in human liver.

Authors:  J Kapitulnik; P J Popper; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875

10.  The effect of alcoholic cirrhosis on the two kinetic components (high and low affinity) of the microsomal 0-deethylation of 7-ethoxycoumarin in human liver.

Authors:  K W Woodhouse; F M Williams; E Mutch; P Wright; O F James; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more
  13 in total

1.  Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity.

Authors:  H Kraul; J Truckenbrodt; A Huster; R Töpfer; A Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.

Authors:  K M Deppermann; H Lode; G Höffken; G Tschink; C Kalz; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 3.  Side effects of ranitidine.

Authors:  T Vial; C Goubier; A Bergeret; F Cabrera; J C Evreux; J Descotes
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

4.  Effect of vigabatrin and gabapentin on phynytoin pharmacokinetics in the dog.

Authors:  K M Matar; P J Nicholls; A Tekle; S A Bawazir; M I al-Hassan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

5.  A comparison of the influence of famotidine and cimetidine on phenytoin elimination and hepatic blood flow.

Authors:  N C Sambol; R A Upton; A N Chremos; E T Lin; R L Williams
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

Review 6.  Fluoroquinolones: interaction profile during enteral absorption.

Authors:  K M Deppermann; H Lode
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 7.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 8.  Interactions and non-interactions with ranitidine.

Authors:  W Kirch; H Hoensch; H D Janisch
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

Review 9.  Drug interactions of clinical significance with opioid analgesics.

Authors:  P M Maurer; R R Bartkowski
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

10.  Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity.

Authors:  W Kirch; S Milferstädt; A Halabi; I Rocher; C Efthymiopoulos; L Jung
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.